Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,873,692
  • Shares Outstanding, K 161,974
  • Annual Sales, $ 705,140 K
  • Annual Income, $ -453,900 K
  • EBIT $ -278 M
  • EBITDA $ -287 M
  • 60-Month Beta 0.28
  • Price/Sales 13.06
  • Price/Cash Flow N/A
  • Price/Book 21.40

Options Overview Details

View History
  • Implied Volatility 49.05% (+6.90%)
  • Historical Volatility 25.44%
  • IV Percentile 49%
  • IV Rank 25.83%
  • IV High 86.76% on 04/09/25
  • IV Low 35.92% on 09/08/25
  • Expected Move (DTE 2) 2.55 (3.23%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 42
  • Volume Avg (30-Day) 1,130
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 42,109
  • Open Int (30-Day) 37,432
  • Expected Range 76.34 to 81.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.34
  • Number of Estimates 9
  • High Estimate -0.95
  • Low Estimate -1.62
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -103.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.08 +3.71%
on 01/05/26
86.15 -8.42%
on 01/07/26
-1.92 (-2.38%)
since 12/12/25
3-Month
66.66 +18.36%
on 11/10/25
86.15 -8.42%
on 01/07/26
+7.53 (+10.55%)
since 10/14/25
52-Week
23.95 +229.44%
on 04/09/25
86.15 -8.42%
on 01/07/26
+46.21 (+141.36%)
since 01/14/25

Most Recent Stories

More News
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 Biogen...

IONS : 79.25 (-0.29%)
BIIB : 170.26 (-4.51%)
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

– TRYNGOLZA® (olezarsen) outperforms expectations, achieved 2025 preliminary U.S. net product sales of $105M* as first FDA-approved treatment for FCS; sNDA for sHTG submitted for review –...

IONS : 79.25 (-0.29%)
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

– Primary endpoint met in both trials – – Bepirovirsen demonstrated a statistically significant and clinically meaningful...

IONS : 79.25 (-0.29%)
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44 th Annual J.P. Morgan Healthcare...

IONS : 79.25 (-0.29%)
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

– First and only investigational medicine for this rare, often fatal neurological condition – – On track to submit new drug application (NDA) in Q1 2026 –

IONS : 79.25 (-0.29%)
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

– On track to submit supplemental new drug application by end of year –

IONS : 79.25 (-0.29%)
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg...

IONS : 79.25 (-0.29%)
BIIB : 170.26 (-4.51%)
Biogen Completes Acquisition of Alcyone Therapeutics

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative...

IONS : 79.25 (-0.29%)
BIIB : 170.26 (-4.51%)
DAWNZERAâ„¢ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Recommendation based on breadth of clinical evidence demonstrating significant HAE attack rate reduction with DAWNZERA European Commission decision expected...

IONS : 79.25 (-0.29%)
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity

IONS : 79.25 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 85.79
2nd Resistance Point 84.18
1st Resistance Point 81.83
Last Price 79.25
1st Support Level 77.87
2nd Support Level 76.26
3rd Support Level 73.91

See More

52-Week High 86.15
Last Price 79.25
Fibonacci 61.8% 62.39
Fibonacci 50% 55.05
Fibonacci 38.2% 47.71
52-Week Low 23.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar